Sunnymeath Asset Management Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 34.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,150 shares of the company’s stock after buying an additional 4,390 shares during the period. Eli Lilly and Company makes up approximately 2.5% of Sunnymeath Asset Management Inc.’s investment portfolio, making the stock its 5th largest position. Sunnymeath Asset Management Inc.’s holdings in Eli Lilly and Company were worth $1,162,000 as of its most recent filing with the SEC.
Several other institutional investors have also added to or reduced their stakes in LLY. Tradewinds Capital Management LLC boosted its position in Eli Lilly and Company by 22.3% in the third quarter. Tradewinds Capital Management LLC now owns 1,345 shares of the company’s stock worth $108,000 after buying an additional 245 shares in the last quarter. Integrated Wealth Management raised its position in Eli Lilly and Company by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares during the last quarter. Financial Architects Inc raised its position in Eli Lilly and Company by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares during the last quarter. Tarbox Group Inc. raised its position in Eli Lilly and Company by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock valued at $124,000 after buying an additional 11 shares during the last quarter. Finally, Penserra Capital Management LLC raised its position in Eli Lilly and Company by 100.0% in the third quarter. Penserra Capital Management LLC now owns 1,584 shares of the company’s stock valued at $127,000 after buying an additional 792 shares during the last quarter. Institutional investors and hedge funds own 75.15% of the company’s stock.
Eli Lilly and Company (NYSE:LLY) opened at 77.27 on Monday. Eli Lilly and Company has a one year low of $64.18 and a one year high of $83.79. The company has a 50-day moving average price of $75.99 and a 200-day moving average price of $76.79. The company has a market capitalization of $82.84 billion, a price-to-earnings ratio of 29.97 and a beta of 0.30.
Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, January 31st. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $0.98 by $0.03. Eli Lilly and Company had a return on equity of 24.74% and a net margin of 12.90%. The business had revenue of $5.76 billion for the quarter, compared to the consensus estimate of $5.54 billion. During the same period last year, the firm earned $0.78 earnings per share. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post $4.10 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 10th. Stockholders of record on Wednesday, February 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.67%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $0.51. The ex-dividend date is Monday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 79.07%.
TRADEMARK VIOLATION WARNING: This report was first reported by sleekmoney and is owned by of sleekmoney. If you are viewing this report on another website, it was illegally copied and republished in violation of international trademark & copyright laws. The correct version of this report can be read at http://sleekmoney.com/sunnymeath-asset-management-inc-has-1162000-position-in-eli-lilly-and-company-lly/1657932.html.
A number of equities research analysts have issued reports on LLY shares. J P Morgan Chase & Co set a $85.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a research report on Thursday, November 24th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $95.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, October 26th. Zacks Investment Research upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $88.00 price target on the stock in a research note on Thursday, October 20th. Citigroup Inc. restated a “buy” rating on shares of Eli Lilly and Company in a research note on Tuesday, November 8th. Finally, Jefferies Group LLC restated a “buy” rating and set a $100.00 price target (down previously from $105.00) on shares of Eli Lilly and Company in a research note on Friday, October 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Eli Lilly and Company currently has an average rating of “Buy” and a consensus target price of $86.41.
In related news, Director R David Hoover purchased 500 shares of the firm’s stock in a transaction that occurred on Friday, December 16th. The shares were acquired at an average price of $71.85 per share, for a total transaction of $35,925.00. Following the purchase, the director now owns 33,504 shares in the company, valued at $2,407,262.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Susan Mahony sold 20,242 shares of the company’s stock in a transaction dated Friday, December 16th. The shares were sold at an average price of $72.65, for a total transaction of $1,470,581.30. Following the completion of the transaction, the senior vice president now owns 67,802 shares in the company, valued at approximately $4,925,815.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 470,497 shares of company stock worth $35,358,665. 0.20% of the stock is owned by insiders.
Eli Lilly and Company Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/sunnymeath-asset-management-inc-has-1162000-position-in-eli-lilly-and-company-lly/1657932.html
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.